Obesity, but not diabetes, is associated with greater prostate cancer mortality among men receiving combined modality treatment for local advanced disease, data show.
A study conducted by Matthew R. Smith, MD, PhD, of Massachusetts General Hospital in Boston, analyzed data from 1,554 men who participated in a large randomized clinical trial. The men were treated with radiation therapy and short-term or long-term goserelin for locally advanced prostate cancer. Of 765 deaths, 210 (27%) were attributed to prostate cancer.
After controlling for other covariates, the presence of diabetes was associated with a twofold greater risk of death from all causes and death from causes other than prostate cancer, researchers reported in the Journal of Clinical Oncology (2008;26:4333-4339). Diabetes did not affect prostate cancer mortality. Obesity, however, increased the risk of prostate cancer death twofold.
The investigators said their observations suggest that the association between obesity and increased prostate cancer mortality is mediated by a mechanism or mechanisms other than the characteristic metabolic alterations of diabetes.